• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

    3.410 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,195
    Open 3.410
    Bid (Size) 3.350 (100)
    Ask (Size) 3.420 (100)
    Prev. Close 3.410
    Today's Range 3.410 - 3.410
    52wk Range 2.530 - 5.450
    Shares Outstanding 65,837,894
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    -1.4%
    -1.4%
    1 Month
    -14.5%
    -14.5%
    3 Month
    -5.5%
    -5.5%
    6 Month
    -2.0%
    -2.0%
    1 Year
    +11.1%
    +11.1%

    More News

    Read More
    News headline image
    Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Rocket Pharmaceuticals Inc (NASDAQ:RCKT) Posts Narrower Q3 2025 Loss, Advances Gene Therapy Pipeline ↗
    Via Chartmill
    News headline image
    Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
    Via Benzinga
    News headline image
    ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock ↗
    Via Benzinga
    News headline image
    Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy ↗
    Via Stocktwits
    News headline image
    FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗
    Via Benzinga
    News headline image
    Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Coty, Bilibili, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Rocket Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Rocket Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Rocket Pharmaceuticals, Inc. - Common Stock trade on?
    Rocket Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock is RCKT on the Nasdaq Stock Market
    What is the current price of Rocket Pharmaceuticals, Inc. - Common Stock?
    The current price of Rocket Pharmaceuticals, Inc. - Common Stock is 3.410
    When was Rocket Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Rocket Pharmaceuticals, Inc. - Common Stock was at 08/03/26 04:00 PM ET
    What is the market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock is 224.51M
    How many shares of Rocket Pharmaceuticals, Inc. - Common Stock are outstanding?
    Rocket Pharmaceuticals, Inc. - Common Stock has 225M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.